Safety and Efficacy Study of Pegylated Interferon Lambda Versus Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C

NCT01447394 · clinicaltrials.gov ↗

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus (HCV)

Interventions

BIOLOGICAL: Pegylated Interferon Lambda
BIOLOGICAL: Pegylated Interferon Alfa-2a
DRUG: Ribavirin

Sponsor

Bristol-Myers Squibb